 | Up a level |
Chan, A. T. C. and Lee, V. H. F. and Hong, R-L and Ahn, M. -J. and Chong, W. Q. and Kim, S. -B. and Ho, G. F. and Caguioa, P. B. and Ngamphaiboon, N. and Ho, C. and Aziz, M. A. S. A. and Ng, Q. S. and Yen, C. -J. and Soparattanapaisarn, N. and Ngan, R. K. -C and Kho, S. K. and Tiambeng, M. L. A. and Yun, T. and Sriuranpong, V. and Algazi, A. P. and Cheng, A. and Massarelli, E. and Swaby, R. F. and Saraf, S. and Yuan, J. and Siu, L. L. (2023) Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. Annals of Oncology, 34 (3). pp. 251-261. ISSN 0923-7534, DOI https://doi.org/10.1016/j.annonc.2022.12.007.
